In vivo molecular imaging of HER2 expression in a rat model of Barrett's esophagus adenocarcinoma.

Human epidermal growth factor receptor 2 (HER2) is involved in the malignant progression of several human cancers, including esophageal adenocarcinoma (EAC). The purpose of this study was to evaluate HER2 overexpression and to explore the feasibility of confocal laser endomicroscopy for in vivo molecular imaging of HER2 status in an animal model of Barrett's-related EAC. Rats underwent esophagojejunostomy with gastric preservation. At 30 weeks post-surgery, the esophagus of 46 rats was studied; endoscopic and histological findings were correlated with HER2 immunofluorescence on excised biopsies and gross specimens. At this age, 23/46 rats developed Barrett's esophagus (BE), and 6/46 had cancer (four EAC and two squamous cell carcinomas). A significant overexpression of HER2 was observed in esophageal adenocarcinoma compared with normal squamous esophagus (9.4-fold) and BE (6.0-fold). AKT and its phosphorylated form were also overexpressed in cancer areas. Molecular imaging was performed at 80 weeks post-surgery in four rats after tail injection of fluorescent-labeled anti-HER2 antibody. At this age, 3/4 rats developed advance adenocarcinoma and showed in vivo overexpression of HER2 by molecular confocal laser endomicroscopy with heterogeneous distribution within cancer; no HER2 signal was observed in normal or Barrett's tissues. Therefore, HER2 overexpression is a typical feature of the surgical induced model of EAC that can be easily quantified in vivo using an innovative mini-invasive approach including confocal endomicroscopy; this approach may avoid limits of histological evaluation of HER2 status on 'blinded' biopsies.

[1]  B. Liu,et al.  Development of esophageal metaplasia and adenocarcinoma in a rat surgical model without the use of a carcinogen. , 1997, Carcinogenesis.

[2]  R. Cestari,et al.  TOPOIIα and HER-2/neu overexpression/amplification in Barrett’s oesophagus, dysplasia and adenocarcinoma , 2010, Histopathology.

[3]  Martin Goetz,et al.  Molecular in vivo imaging of gastric cancer in a human-murine xenograft model: targeting epidermal growth factor receptor. , 2012, Gastrointestinal endoscopy.

[4]  Katherine S. Garman,et al.  Review: Experimental models for Barrett's esophagus and esophageal adenocarcinoma. , 2012, American journal of physiology. Gastrointestinal and liver physiology.

[5]  M. Rugge,et al.  Human epithelial growth factor receptor 2 (HER2) status in primary and metastatic esophagogastric junction adenocarcinomas. , 2012, Human pathology.

[6]  K. Danenberg,et al.  Validation of a rodent model of Barrett’s esophagus using quantitative gene expression profiling , 2009, Surgical Endoscopy.

[7]  R. Langer,et al.  Assessment of ErbB2 (Her2) in oesophageal adenocarcinomas: summary of a revised immunohistochemical evaluation system, bright field double in situ hybridisation and fluorescence in situ hybridisation , 2011, Modern Pathology.

[8]  Kenneth K Wang,et al.  Updated Guidelines 2008 for the Diagnosis, Surveillance and Therapy of Barrett's Esophagus , 1998, The American Journal of Gastroenterology.

[9]  G. Sauter,et al.  HER-2 amplification is highly homogenous in gastric cancer. , 2010, Human pathology.

[10]  O. Ogunwobi,et al.  Activation of Akt is increased in the dysplasia-carcinoma sequence in Barrett's oesophagus and contributes to increased proliferation and inhibition of apoptosis: a histopathological and functional study , 2007, BMC Cancer.

[11]  M. Rugge,et al.  Early HER2 dysregulation in gastric and oesophageal carcinogenesis , 2012, Histopathology.

[12]  M. Moasser.  The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis , 2007, Oncogene.

[13]  M. Rugge,et al.  CDX2 hox gene product in a rat model of esophageal cancer , 2009, Journal of experimental & clinical cancer research : CR.

[14]  J. T. Jørgensen.  Targeted HER2 Treatment in Advanced Gastric Cancer , 2010, Oncology.

[15]  H. Sugihara,et al.  Cell kinetic study on histogenesis of Barrett's esophagus using rat reflux model. , 2003, Scandinavian journal of gastroenterology.

[16]  R. Kiesslich,et al.  Confocal endomicroscopy: in vivo diagnosis of neoplastic lesions of the gastrointestinal tract. , 2008, Anticancer research.

[17]  A. Jemal,et al.  Cancer statistics, 2012 , 2012, CA: a cancer journal for clinicians.

[18]  T. Lange,et al.  Trastuzumab has anti-metastatic and anti-angiogenic activity in a spontaneous metastasis xenograft model of esophageal adenocarcinoma. , 2011, Cancer Letters.

[19]  E. Cho,et al.  HER-2/neu Amplification Is an Independent Prognostic Factor in Gastric Cancer , 2006, Digestive Diseases and Sciences.

[20]  L. Pecciarini,et al.  HER2 Testing in Gastric Cancer , 2011, Advances in anatomic pathology.

[21]  R. Langer,et al.  Successful evaluation of a new animal model using mice for esophageal adenocarcinoma , 2010, Langenbeck's Archives of Surgery.

[22]  A. Polglase,et al.  Confocal laser endoscopy for diagnosing intraepithelial neoplasias and colorectal cancer in vivo. , 2004, Gastroenterology.

[23]  P. Rigotti,et al.  Heterotopic cardiac xenotransplantation in rodents: Report of a refined technique in a hamster‐to‐rat model , 2005, Microsurgery.

[24]  R. Conigliaro,et al.  Advances in Endoscopic Visualization of Barrett's Esophagus: The Role of Confocal Laser Endomicroscopy , 2012, Gastroenterology research and practice.

[25]  M. J. van de Vijver,et al.  Assessment of a HER2 scoring system for gastric cancer: results from a validation study , 2008, Histopathology.

[26]  R. Cestari,et al.  Targeted therapy with trastuzumab in dysplasia and adenocarcinoma arising in Barrett's esophagus: a translational approach. , 2008, Minerva gastroenterologica e dietologica.

[27]  Thomas D. Wang,et al.  Molecular imaging in gastrointestinal endoscopy. , 2010, Gastroenterology.

[28]  Yoon-Koo Kang,et al.  Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial , 2010, The Lancet.

[29]  P. Pfau,et al.  Probe-Based Confocal Laser Endomicroscopy to Guide Real-Time Endoscopic Therapy in Barrett's Esophagus with Dysplasia , 2012, Case Reports in Gastroenterology.

[30]  A. Gavin,et al.  Risk of malignant progression in Barrett's esophagus patients: results from a large population-based study. , 2011, Journal of the National Cancer Institute.

[31]  A. Thrift,et al.  Current Status and Future Perspectives on the Etiology of Esophageal Adenocarcinoma , 2011, Front. Oncol..

[32]  D. Hicks,et al.  HER2 testing in gastric and esophageal adenocarcinoma: new diagnostic challenges arising from new therapeutic options , 2012, Biotechnic & histochemistry : official publication of the Biological Stain Commission.

[33]  F. Schmitt,et al.  Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients , 2009, British Journal of Cancer.

[34]  T. Hattori,et al.  Reflux of duodenal or gastro‐duodenal contents induces esophageal carcinoma in rats , 1996, International journal of cancer.

[35]  D. Hicks,et al.  HER2 Testing in Gastric and Gastroesophageal Junction Cancers: A New Therapeutic Target and Diagnostic Challenge , 2011, Applied immunohistochemistry & molecular morphology : AIMM.

[36]  J. Crawford,et al.  Endoscopic evaluation of esophago-gastro-jejunostomy in rat model of Barrett's esophagus. , 2009, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus.

[37]  A. Jimeno,et al.  HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[38]  A. Bhardwaj,et al.  Barrett's Esophagus: Emerging Knowledge and Management Strategies , 2012, Pathology research international.

[39]  R. Kiesslich,et al.  In vivo molecular imaging of epidermal growth factor receptor in patients with colorectal neoplasia using confocal laser endomicroscopy. , 2013, Cancer letters.